CytomX Therapeutics, Inc.
(NASDAQ : CTMX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen Inc.
-0.32%357.551.2%$827.84m
AMGNAmgen Inc.
-0.31%189.901.2%$541.43m
CELGCelgene Corporation
0.31%85.361.2%$509.09m
GILDGilead Sciences, Inc.
0.32%77.620.9%$474.98m
VRTXVertex Pharmaceuticals Incorporated
0.19%177.731.9%$314.12m
REGNRegeneron Pharmaceuticals, Inc.
-0.32%365.952.6%$276.01m
ILMNIllumina, Inc.
0.72%313.393.5%$271.32m
BLUEBluebird Bio, Inc.
-0.44%179.5515.7%$196.65m
SRPTSarepta Therapeutics, Inc.
-0.49%132.6616.6%$195.85m
ALXNAlexion Pharmaceuticals, Inc.
-0.58%134.382.0%$177.53m
NKTRNektar Therapeutics
1.25%49.345.6%$174.18m
EXASExact Sciences Corporation
-0.10%67.5525.4%$155.54m
EXELExelixis, Inc.
0.14%21.326.4%$135.55m
BMRNBioMarin Pharmaceutical Inc.
0.46%102.374.4%$123.21m
AAgilent Technologies, Inc.
-0.03%63.831.5%$110.52m

Company Profile

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.